Does hydroxyapatite remineralise teeth?

Yes — for early enamel lesions, laboratory and in-situ studies show that hydroxyapatite (HA) can support remineralisation. Clinical evidence is growing but still narrower than fluoride’s. HA does not “regrow” a tooth or fill a cavity that already needs a restoration.

That distinction — early mineral loss versus a hole — is the whole story. Everything below hangs on it.

What remineralisation actually means

Tooth enamel is mostly mineral — biological apatite closely related to hydroxyapatite. Acids from plaque bacteria (caries) or from diet (erosion) dissolve mineral from the surface and subsurface. Demineralisation is that loss. Remineralisation is mineral returning to partially demineralised tissue, helped by saliva’s calcium and phosphate, and often by toothpaste actives.

A white spot lesion is a classic early-caries appearance: mineral has been lost under a relatively intact surface. At that stage, non-invasive repair is often still possible. Once the surface collapses into a cavity, remineralising pastes are not a substitute for a filling.

Healthy mouths already remineralise every day. After a meal, plaque pH can drop; saliva then buffers acid and supplies ions that rebuild the outermost enamel. Toothpaste actives tip that balance. They do not invent remineralisation from nothing.

Children’s enamel and newly erupted teeth can be especially vulnerable during the years after eruption, which is one reason paediatric caries trials and in-situ white-spot studies attract so much attention. Adult root surfaces (cementum and exposed dentin) remineralise under different rules than crown enamel — another reason not to over-generalise a single lab protocol to every tooth surface.

For the chemistry of enamel mineral itself, start with what hydroxyapatite is.

Proposed mechanisms for HA

Reviews of HA’s modes of action (including Enax et al., 2019) describe several overlapping ideas:

1. Particle deposition — HA particles adhere to enamel, occupy micropores, and form a mineral-rich surface layer.
2. Ion reservoir — dissolution of HA releases Ca²⁺ and PO₄³⁻, raising local supersaturation so remineralisation is favoured under pH cycling.
3. Biomimetic bridging — mineral–mineral contact between synthetic particles and residual enamel crystallites.

These mechanisms are not mutually exclusive. A paste can leave particles on the surface and contribute dissolved ions. Which pathway dominates in a given product likely depends on particle size, concentration, saliva chemistry, and how long slurry stays on the teeth before rinsing.

How that differs from fluoride

Fluoride works differently. It promotes formation of a more acid-resistant fluorapatite-like mineral and inhibits demineralisation, drawing on salivary calcium and phosphate. HA can supply mineral more directly. Those are complementary logics, not identical ones — which is why a head-to-head hydroxyapatite vs fluoride comparison needs both mechanisms on the table.

Fluoride does not “build enamel out of fluoride alone.” It catalyses and stabilises remineralisation from saliva. HA’s pitch is that it brings calcium-phosphate mineral to the party as particles and ions. Neither story cancels diet, saliva flow, or plaque control.

Evidence by study type

Researchers use three nested levels of evidence. Confusing them is how product pages overclaim.

In vitro (laboratory)

Artificial enamel lesions are demineralised, treated with HA pastes or slurries, then measured for surface microhardness, mineral content, or imaged with SEM.

Huang et al. (2009) tested nano-HA concentrations from 1% to 15% under pH cycling. Remineralisation increased with concentration up to about 10%; 10% and 15% performed similarly — a plateau. That study is one reason ~10% became a common research and premium retail target. It does not prove that more than 10% is always better in a real mouth. Aggregation and formulation challenges also rise at high loadings (noted in scoping reviews such as Anil et al., 2022).

In-vitro work is controlled and informative for mechanism. It is also optimistic: standardised lesions, controlled acid challenges, and no years of cumulative behavioural risk.

In situ (in the mouth, still not a full clinical trial)

In-situ studies place enamel specimens in appliances worn by volunteers, so real saliva and oral conditions act on the samples. They sit between the lab bench and a full randomised clinical trial.

Najibfard et al., 2011 (Journal of Clinical Dentistry): nano-HA dentifrices at 5% and 10% remineralised early lesions. Mineral gain was comparable between the two concentrations and versus an 1100 ppm fluoride dentifrice in that protocol. Small samples and short duration apply, but the finding matters for the “is 10% mandatory?” question — see also 5% vs 10% hydroxyapatite.

Amaechi et al., 2019 (BDJ Open): hydroxyapatite toothpaste compared with amine fluoride for prevention and remineralisation of white spot lesions in a children’s in-situ model; HA was non-inferior in that design.

Amaechi et al., 2022: a 20% HAP toothpaste remineralised molar–incisor hypomineralisation (MIH) lesions in situ, with a higher percentage remineralisation than 1450 ppm fluoride under that specific protocol. MIH is a developmental enamel defect, not ordinary early caries. Treat the result as promising for that indication and protocol — not as a blanket claim that HA beats fluoride everywhere.

Clinical trials (caries and lesions in real patients)

Clinical remineralisation is often inferred from caries endpoints or white-spot outcomes rather than from microscopic mineral maps on extracted teeth.

• Randomised non-inferiority trials of 10% microcrystalline HA toothpastes (Schlagenhauf 2019; Paszynska 2021 and 2023) compared fluoride controls on caries-related endpoints. Those are clinical support for cavity-adjacent outcomes, detailed in hydroxyapatite and cavity prevention.
• Systematic reviews of nano-HA for white spot lesions report promising mineral and microhardness effects, but also high heterogeneity and risk-of-bias concerns. Supportive, not definitive.
• A 2024–2025 Journal of Dentistry update on caries prevention by HA concludes clinical non-inferiority evidence is strengthened but still based on few trials.

White spot lesions and “enamel repair” language

White spots after orthodontics are a frequent reason people search for remineralising pastes. Brackets make cleaning harder; early lesions bloom as chalky patches. In-situ work (including Amaechi 2019) speaks directly to that use case. Clinical orthodontic caries data appear in Schlagenhauf 2019 — a six-month non-inferiority RCT in high-risk bracketed patients using 10% microcrystalline HA versus a fluoride control.

Even here, language discipline matters:

• Supports remineralisation of early lesions — aligned with the literature
• Rebuilds enamel / regrows enamel / reverses cavities — overclaim for cavitated disease; misleading for macroscopic thickness loss

If the surface is broken through, see a dentist. Remineralisation is not a home filling.

Nano vs micro — does size change remineralisation?

Nano particles have higher surface area and may access microscopic defects and tubules more readily. That is mechanistically plausible and appears throughout in-vitro / in-situ narratives. Commercial nHA is often described around 20–100 nm; EU dossier examples include rod-shaped particles with median dimensions on the order of tens of nanometres.

It is not established that nano-HA is clinically superior to microcrystalline HA for caries prevention in large head-to-head RCTs. Several pivotal caries trials used microcrystalline 10% HA. Conflating “nano” marketing with those trial results is a common error. Details: nano-hydroxyapatite vs hydroxyapatite.

Concentration: 5%, 10%, and “more is better”

Prefer “studied at” language over “more percent is always better.” Going far above 10% has limited incremental evidence for standard stoichiometric systems and can create formulation challenges.

Remineralisation is not the same as erosion repair or bleaching

Acid erosion removes mineral from the surface in a different pattern than caries. HA’s proposed “sacrificial layer” may buffer acid attacks in lab and short in-situ work; long-duration clinical erosion RCTs are limited for ethical and practical reasons. See hydroxyapatite and enamel erosion.

Whitening with HA is usually framed as surface repair plus light scatter — not peroxide bleaching. Remineralisation can improve the appearance of chalky spots; it is not a shade-guide guarantee. Clinical whitening evidence is modest and preliminary relative to bleaching.

Sensitivity relief often travels with remineralisation marketing, but the dominant mechanism there is tubule occlusion, not bulk enamel regrowth. See HA for sensitive teeth.

What HA cannot do

• Reverse a cavitated lesion that needs operative care
• Replace professional treatment for active decay, pain, or abscess
• Guarantee remineralisation if acid challenge stays high (frequent sugar, dry mouth, poor plaque control)
• Match fluoride’s volume of independent, multi-year public-health evidence
• Prove clinical superiority to fluoride for caries on current data

How long does remineralisation take?

There is no universal consumer timer. Lab pH-cycling and in-situ protocols often run days to a few weeks. Clinical programmes measure months. Lesion depth, saliva quality, brushing frequency, rinsing habits, and ongoing acid exposure all matter.

Practically: use the paste consistently twice a day, give it contact time (how to use HA toothpaste), and judge progress with a dentist for monitored white spots — not with overnight expectations.

Saliva, diet, and why toothpaste is not the whole story

Even the best remineralising paste works inside a mouth that already has rules. Low saliva (xerostomia), frequent snacking on fermentable carbohydrates, orthodontic appliances, and gastro-oesophageal reflux all increase demineralisation pressure. Under those conditions, mineral gain is harder to hold.

That is why clinical advice still emphasises behaviour and professional risk assessment alongside product choice. HA can support early repair; it cannot outrun a constant acid bath.

People with dry mouth from medications, Sjögren’s syndrome, or head-and-neck radiation need clinician-guided plans that may include high-fluoride products, saliva substitutes, or other therapies. An HA paste can be part of a comfort-oriented routine for some of those patients, but it should not be framed as a solo solution drawn from a blog.

Reading product claims against this evidence map

When a label or landing page says “repairs enamel” or “remineralises teeth,” ask:

1. Is the claim tied to early lesions, or does it imply fixing cavities?
2. Does the brand cite in-vitro, in-situ, or clinical work — and which?
3. Was the studied product micro or nano, and at what percentage?
4. Is the cited trial industry-funded? (Often yes for HA — still reportable, still disclose.)
5. Are they comparing to fluoride fairly, or implying superiority the papers do not claim?

If those answers are vague, the science page you are reading is doing more work than the advertisement.

Other remineralising systems (CPP-ACP, bioactive glass, xylitol) have their own mechanisms and evidence shapes. They are not secret forms of HA. Side-by-side discussion: HA vs CPP-ACP, NovaMin, and xylitol.

A short glossary for this topic

• Demineralisation — mineral loss from enamel or dentin under acid
• Remineralisation — mineral return to partially demineralised tissue
• White spot lesion (WSL) — early caries appearance; chalky opacity
• ICDAS — clinical scoring system for caries severity used in some trials
• DMFS — decayed, missing, filled surfaces (a clinical caries index)
• In situ — specimens worn in the mouth; real saliva, not a full patient outcome trial
• Non-inferiority — “not unacceptably worse than control within a margin,” not “proven better”

Practical takeaways

1. Early lesions are the remineralisation target; fillings address cavities.
2. Both 5% and 10% HA have supportive remineralisation data; 10% is the concentration most used in caries RCTs.
3. Separate in vitro, in situ, and clinical claims when you read product pages.
4. Fluoride remains the default evidence heavyweight; HA is a biomimetic alternative with growing data — not a proven superior replacement.
5. Industry-funded positive findings still count — but they should be labelled as such and weighed against the fluoride evidence base.
6. Contact time and consistent twice-daily use matter more than chasing exotic percentages above the studied range.

For buying criteria tied to concentration and labels, use the buyer’s guide. For cavity endpoints specifically, continue to hydroxyapatite and cavity prevention. Safety and ingestion questions belong on is hydroxyapatite toothpaste safe?.